Healthcare utilization associated with immune-related adverse events in gastrointestinal malignancies: A systematic review and meta-analysis.
366 Background: Immune checkpoint inhibitors (ICIs) improve outcomes across gastrointestinal (GI) malignancies but may increase healthcare utilization through severe immune-related adverse events (irAEs), hospitalization, corticosteroid exposure, and treatment discontinuation. We evaluated the pooled burden of...